Combined chemotherapy including rifabutin for rifampicin and isoniazid resistant pulmonary tuberculosis

S. Pretet, A. Lebeaut, R. Parrot, C. Truffot, J. Grosset, A. T. Dinh-Xuan

Research output: Contribution to journalArticlepeer-review

Abstract

A prospective multicentre open study has been conducted in France in order to assess the efficacy and tolerability of an antimycobacterial regimen including rifabutin in the treatment of patients with pulmonary tuberculosis due to rifampicin and isoniazid resistant bacilli. Patients were treated with daily rifabutin (450-600 mg), associated with companion drugs to which the organisms remained susceptible; in most cases the regimen included a fluoroquinolone. The duration of treatment was initially scheduled for a minimum period of 12 months after sputum culture conversion. Thirty-nine patients were enrolled, 23 of whom were treated for at least 12 months. Culture conversion was obtained at the end of the twelfth month in 14 out of 23 patients. Twenty-one out of 39 patients experienced adverse events. These were, however, serious enough to discontinue treatment in only four patients. These results suggest that an antimycobacterial combination including rifabutin might contribute to the treatment of multi-resistant pulmonary tuberculosis.

Original languageEnglish (US)
Pages (from-to)680-684
Number of pages5
JournalEuropean Respiratory Journal
Volume5
Issue number6
StatePublished - Jan 1 1992

Keywords

  • mycobacterial infection
  • rifabutin
  • rifampicin and isoniazid resistant bacilli

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Combined chemotherapy including rifabutin for rifampicin and isoniazid resistant pulmonary tuberculosis'. Together they form a unique fingerprint.

Cite this